title: The risk of asthma mortality with inhaled long acting beta-agonists.
abstract: This article reviews the available evidence as to whether inhaled long acting beta-agonists (LABA) increase the risk of asthma mortality and considers the implications for the use of this treatment in the management of asthma. Randomised controlled trials suggest that LABAs prescribed as monotherapy may increase the risk of asthma death in certain circumstances, such as the unsupervised "off-label" use without concomitant inhaled corticosteroid (ICS) treatment in patients with unstable asthma. However, there is also evidence that the use of LABAs in conjunction with ICS treatment in adult asthma as recommended in current guidelines is not associated with an increased risk of asthma mortality. The only way in which a prescriber can ensure that a patient with asthma takes LABA treatment in conjunction with ICS is through a combination ICS/LABA product, an approach which may have additional therapeutic advantages. We propose that in the management of asthma, a case can now be made to limit the availability of LABAs to combination LABA/ICS therapy.
authors.affiliation: Medical Research Institute of New Zealand, Wellington, New Zealand.
authors.forename: M
authors.initials: M
authors.lastname: Wijesinghe
authors.forename: K
authors.initials: K
authors.lastname: Perrin
authors.forename: M
authors.initials: M
authors.lastname: Harwood
authors.forename: M
authors.initials: M
authors.lastname: Weatherall
authors.forename: R
authors.initials: R
authors.lastname: Beasley
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D004983:Ethanolamines / Q000008:administration & dosage*; D000068759:Formoterol Fumarate; D006801:Humans; D015201:Meta-Analysis as Topic; D009026:Mortality / Q000639:trends; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000068299:Salmeterol Xinafoate; D055815:Young Adult
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate